NTRK fusion positive cancer
MONDO:0700215Neoplasm associated with the expression of a Neurotrophic Tyrosine Receptor Kinase (NTRK) Fusion. NTRK fusion-positive tumors have been identified in a broad range of solid tumor types, including breast, cholangiocarcinoma, colorectal, gynecological, neuroendocrine, non-small cell lung, salivary gland, pancreatic, sarcoma and thyroid cancers.
Also known as: NTRK fusion positive neoplasm, NTRK fusion positive solid tumor, NTRK fusion positive solid tumour, neurotrophic tyrosine receptor kinase fusion positive cancer, neurotrophic tyrosine receptor kinase fusion positive neoplasm, neurotrophic tyrosine receptor kinase fusion positive solid tumor, neurotrophic tyrosine receptor kinase fusion positive solid tumour
1450 clinical trials for this condition and its sub-types, 19 tagged with NTRK fusion positive cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New drug shrinks tumors in patients with rare gene mutation
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with various solid cancers that have a specific change in the NTRK gene. The drug is taken orally and works by blocking the action of the altered gene. The main goal was to see how many patients had their tumors shrink or dis…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase 1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Spanish study looks back at targeted cancer Drug's Real-World impact
Knowledge-focused CompletedThis study looked back at the medical records of 19 Spanish patients with rare NTRK fusion cancers who received the targeted drug larotrectinib before it was widely available. The goal was to see how well the drug worked in real-world settings. The study did not involve new treat…
Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC